Q2 roll call for mid-sized pharma, as companies face generics trough

Share this article:
First-half earnings are in for Allergan, Shire and UCB, with the three companies striking an upbeat tone on revenues, despite the generics trough.

Allergan sales rose 5%, to $1.5 billion for the quarter ended June 30, compared to sales of $1.4 billion for the same period last year. The company said in a statement Wednesday that specialty pharma had a 5% boost in sales over the same period last year, and medical devices also rose, outpacing last year's sales by 4%. Looking ahead, the company said it expects sales to be between $5.6 billion and $5.9 billion for the year. Leerink Swann analyst Seamus Fernandez said in his August 1 research note that the earnings forecast reflects some downward revisions, including a lower guidance for the firm's eye-pressure drop Lumigan, its filler franchises and its medical device divisions. Fernandez noted that a July survey of dermatologists and plastic surgeons indicated a sluggish Q2 for fillers like Botox, but about a 5% increase between July 2012 and 2013.

Shire's second-quarter results continued the positive turnover trend, despite the influx of generic Adderall XR from Watson into the ADHD marketplace. Sales were $1.2 billion for the quarter, a 16% increase over sales for the same period last year. Strong sellers included ADHD medicine Vyvanase, which had $266 million in sales, a 46% boost over sales for the same period last year. Sales of the Gaucher disease medication Vpriv were $83 million, up 31% over sales for the same period last year, and ADHD medication InTuniv had a 16% sales boost, rising to $70 million compared to sales for the same period in 2011. Adderall XR sales fell to $134 million, a 9% drop from sales during Q2 2011, an expected fall-off from the debut of Watson's copy cat (two authorized generic versions are made by Impax and Teva). The company said it still expects the brand to be a sales contributor, despite the lower-cost competition.

UCB didn't break out quarterly results Wednesday but did say things were going as expected. The Brussels-based drugmaker said its sales rose to $2.1 billion during the first two quarters, a 2% increase over sales for the same period last year. The company said sales of its Crohn's/RA drug Cimzia increased 46% over last year, at $256 million, while sales of the now-generic epilepsy drug Keppra fell to $545 million, a 12% drop from sales for the same period last year. The company said it expects sales of Cimzia, epilepsy drug Vimpat and Parkinson's disease/restless legs syndrome treatment Neupro to be the main drivers for the year's sales.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...